DLL3-expressing Tumors clinical trials at UCSF

1 in progress, 0 open to eligible people

Showing trials for

  • Tarlatamab in Advanced Delta-like 3 (DLL3)-Expressing Tumors Including Neuroendocrine Neoplasms

    Sorry, not currently recruiting here

    This study is being done to learn more about the drug tarlatamab in people with your condition. The purpose of this study is to see the efficacy (how well something works) of study treatment (tarlatamab) and whether it causes any side effects. Tarlatamab is being developed as an anti-cancer drug for tumors and is FDA-approved for extensive-stage small cell lung cancer. Tarlatamab is investigational for the purpose of this study.

    San Francisco, California and other locations

Our lead scientists for DLL3-expressing Tumors research studies include .

Last updated: